GLMD | tickerfilter.com

Fundamental analysis

27%

Profitability 25%

Dept financing 3%

Liquidity 50%

Performance 28%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.99%

1 Month

-31.40%

3 Months

-55.17%

6 Months

-66.75%

1 Year

234.45%

2 Year

-98.30%

Key data

Stock price

$1.30

P/E Ratio

0.00

DAY RANGE

$1.21 - $1.35

EPS

-$0.97

52 WEEK RANGE

$0.24 - $23.80

52 WEEK CHANGE

$225.00

MARKET CAP

15.953 M

YIELD

N/A

SHARES OUTSTANDING

5.045 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$69,218

AVERAGE 30 VOLUME

$2,388,049

Company detail

CEO: Allen Baharaff
Region: US
Website: galmedpharma.com
Employees: 20
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Galmed Pharmaceuticals Ltd. develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.

GLMD - Galmed Pharmaceuticals Ltd